As announced on January 6, 2016, Medicure has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. and Apicore US LLC.
The collaborative project is focused on the development of an intravenous abbreviated New Drug Application ("ANDA") drug product for an acute cardiovascular indication. Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights. Medicure announced on December 13, 2016, the filing of the ANDA with the U.S. Food and Drug Administration.
Medicure is currently developing additional ANDA opportunities focusing on acute care cardiovascular injectables for the U.S. hospital market.